Nuvectis Pharma is focused on developing innovative precision medicine solutions aimed at addressing serious conditions with unmet medical needs in the field of oncology. The company is advancing its pipeline of products, which includes NXP800 and NXP900, both of which are currently undergoing clinical trials. NXP800 is being evaluated in a phase 1b clinical study for its efficacy in treating patients with ARID1a-mutated ovarian cancer, as well as in patients with advanced or metastatic cholangiocarcinoma. Meanwhile, NXP900 is also in a phase 1 clinical study targeting patients with advanced cancers, highlighting Nuvectis Pharma's commitment to developing targeted therapies for complex oncological conditions.

The technologies employed by Nuvectis Pharma are centered around precision medicine, which involves tailoring treatment strategies based on the specific genetic and molecular characteristics of individual tumors. This approach aims to enhance treatment efficacy and improve patient outcomes by focusing on the unique aspects of each patient's cancer. By leveraging advanced scientific research and clinical trial methodologies, Nuvectis Pharma is positioned to make significant contributions to the field of oncology, particularly for patients with limited treatment options.

United States

Nuvectis Pharma is a biopharmaceutical company that focuses on developing novel targeted therapeutics for cancer treatment, including the oral small molecule inhibitor NXP800 targeting the Heat Shock Factor 1 pathway.

Cancer

Nuvectis Pharma

Ovarian cancer

NXP800 is an orally bioavailable small molecule activator of the GCN2 kinase. 
GCN2 phosphorylates the eukaryotic translation initiation factor 2 (eIF2), which results in lower bulk protein synthesis and in induction of preferential translation of stress-adaptive gene transcripts, such as that encoding the ATF4 transcription regulator. Chronic activation of GCN2 by NXP800 leads to cancer cell death.

NXP800

Non-small cell lung carcinoma

Solid tumor/s

Squamous cancers

NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing a complete shutdown of the signaling pathway, in contrast to the currently approved and in-development multi-kinase inhibitors that target SRC but only inhibit its catalytic function. Another key differentiating factor is that NXP900 does not inhibit the ABL kinase, with in vivo data indicating no treatment-related immunosuppression, a potential advantage in the setting of solid tumors.

Nuvectis Pharma

Company Details